Active substances
Ethinylestradiol + Etonogestrel
- SFDA 2
- US FDA 6
- Health Canada 2
- US price lines 1
- NHS prices 1
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| NUVARING VAGINAL RING | 11.7,2.7 mg,mg | Vaginal delivery system · Vaginal use | 1 Implanter | SAR 44.40 | NCE · Prescription | ORGANON | Valid |
| ORNIBEL 0.120 mg / 0.015 mg per 24 Hours | 11,3.474 mg,mg | Implant · Vaginal use | 1 Sachet | SAR 31.55 | Generic · Prescription | EXELTIS GERMANY GmbH | Valid |
Indications — CHI Daman Drug Formulary
CONTRACEPTION; ENDOMETRIOSIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NUVARING | 0.015MG/24HR;0.12MG/24HR | ring · vaginal | ORGANON USA ORGANON | Prescription | 3 Oct 2001 |
| ELURYNG | 0.015MG/24HR;0.12MG/24HR | ring · vaginal | AMNEAL | Prescription | 11 Dec 2019 |
| ETHINYL ESTRADIOL; ETONOGESTREL | 0.015MG/24HR;0.12MG/24HR | ring · vaginal | TEVA PHARMS USA INC | Prescription | 13 Jan 2021 |
| HALOETTE | 0.015MG/24HR;0.12MG/24HR | ring · vaginal | DR REDDYS LABS SA | Prescription | 5 Aug 2022 |
| ENILLORING | 0.015MG/24HR;0.12MG/24HR | ring · vaginal | XIROMED | Prescription | 29 Jun 2023 |
| VERARING | 0.015MG/24HR;0.12MG/24HR | ring · vaginal | DR REDDYS LABS SA | Discontinued | 9 Dec 2021 |
Canada Canada — marketed products (Health Canada)
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | NUVARING VAGINAL RING | $155.70283 | per EA | 22 Jul 2026 |
| NHS Drug Tariff | Ethinylestradiol 2.7mg / Etonogestrel 11.7mg vaginal delivery system | £29.70 | 3 system | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 22.1.6. Intravaginal contraceptives · core
Contact with health services for contraceptive management
Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.